2024
Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study
Sedrak M, Sun C, Bae M, Freedman R, Magnuson A, O’Connor T, Moy B, Wildes T, Klepin H, Chapman A, Tew W, Dotan E, Fenton M, Kim H, Katheria V, Muss H, Cohen H, Gross C, Ji J. Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study. Journal Of Cancer Survivorship 2024, 18: 1131-1143. PMID: 38678525, PMCID: PMC11324395, DOI: 10.1007/s11764-024-01594-3.Peer-Reviewed Original ResearchEarly-stage breast cancerPF-10 scorePF-10Physical functionNon-cancer controlsFunctional declineBC controlOlder breast cancer survivorsRAND 36-Item Short FormBreast cancerCohort of older adultsOlder womenBreast cancer survivorsImprove health outcomesPhysical function subscalePhysical function declineAccelerated functional declineBreast Cancer StudyCancer survivorsFunction subscaleHealth outcomesGroup of womenOlder adultsControl groupShort form
2023
Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States.
Richman I, Long J, Soulos P, Wang S, Gross C. Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States. Annals Of Internal Medicine 2023, 176: 1172-1180. PMID: 37549389, PMCID: PMC10623662, DOI: 10.7326/m23-0133.Peer-Reviewed Original ResearchConceptsCumulative incidenceBreast cancerBreast cancer screeningUnscreened womenOlder womenCancer screeningBreast cancer-specific deathBreast cancer overdiagnosisService Medicare claimsRetrospective cohort studyCancer-specific deathBreast cancer deathsWomen 70 yearsHarms of overdiagnosisNational Cancer InstituteBreast cancer diagnosisCohort studyCancer overdiagnosisCancer deathSEER programMedicare claimsCancer InstituteOverdiagnosisGreater incidenceCancerFalls and hospitalization during chemotherapy in older women with early breast cancer.
Ji J, Sun C, Wildes T, Freedman R, Magnuson A, O'Connor T, Moy B, Klepin H, Chapman A, Tew W, Dotan E, Fenton M, Kim H, Bae M, Katheria V, Gross C, Muss H, Cohen H, Sedrak M. Falls and hospitalization during chemotherapy in older women with early breast cancer. Journal Of Clinical Oncology 2023, 41: 12035-12035. DOI: 10.1200/jco.2023.41.16_suppl.12035.Peer-Reviewed Original ResearchRisk of hospitalizationEarly breast cancerFall historyBreast cancerOlder adultsOlder womenStage II/III diseaseProspective multicenter studyMultivariable logistic regressionSelf-reported fall historyAdjuvant chemoCommon toxicitiesFebrile neutropeniaPrimary endpointPrimary prophylaxisGeriatric assessmentOlder patientsClinical factorsMedian ageAvoidable complicationsMulticenter studyClinical covariatesTreatment decisionsHospitalizationWomen's age
2022
Genetic testing in privately insured women with surgically treated breast cancer
Dinan M, Pitafi S, Greenup R, Long J, Gross C. Genetic testing in privately insured women with surgically treated breast cancer. Breast Cancer Research And Treatment 2022, 198: 177-181. PMID: 36542252, DOI: 10.1007/s10549-022-06829-4.Peer-Reviewed Original ResearchConceptsBreast cancerGenetic testingRoutine breast cancer careBRCA1/BRCA2 genetic testingHormone receptor statusBreast cancer careInvasive breast cancerBRCA2 genetic testingReceptor statusWomen 50Cancer careAge 45Family historyOlder womenInsurer databaseYoung womenCancerWomenCoverage policiesUnclear implicationsPatientsSurgeryPurposeRatesYearsPrevalenceLow-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial
Sedrak M, Sun C, Ji J, Cohen H, Gross C, Tew W, Klepin H, Wildes T, Dotan E, Freedman R, O'Connor T, Chow S, Fenton M, Moy B, Chapman A, Dale W, Katheria V, Kuderer N, Lyman G, Magnuson A, Muss H. Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial. Journal Of Clinical Oncology 2022, 41: 316-326. PMID: 36455189, PMCID: PMC9839299, DOI: 10.1200/jco.22.01440.Peer-Reviewed Original ResearchConceptsLow relative dose intensityRelative dose intensityAdjuvant chemotherapyHOPE trialDose intensityOlder patientsOlder womenBreast cancer benefitPrespecified secondary analysisCurative-intent treatmentInferior survival outcomesChemotherapy dose intensityKaplan-Meier methodLow performance statusMultivariable logistic regressionLog-rank testOverall survival probabilityToxic side effectsCancer benefitOverall survivalPerformance statusStandard chemotherapySupportive carePrimary outcomeSurvival outcomes
2021
Building a Digital Health Risk Calculator for Older Women with Early-Stage Breast Cancer
Abujarad F, Wang S, Ulrich D, Mougalian S, Killelea B, Fraenkel L, Gross C, Evans S. Building a Digital Health Risk Calculator for Older Women with Early-Stage Breast Cancer. Lecture Notes In Computer Science 2021, 12780: 389-402. DOI: 10.1007/978-3-030-78224-5_27.Peer-Reviewed Original ResearchEarly-stage breast cancerOlder womenBreast cancerRadiation therapyTreatment therapiesEvidence-based treatment decisionsShared-decision modelRisk-benefit informationRisk calculatorRelative riskTreatment decisionsPatient healthDigital health toolsPatient comprehensionTherapyHealth toolsWomenCancerHealthPatientsClinicians
2019
“Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer
Wang SY, Abujarad F, Chen T, Evans SB, Killelea BK, Mougalian SS, Fraenkel L, Gross C. “Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer. Journal Of Geriatric Oncology 2019, 11: 850-859. PMID: 31899199, PMCID: PMC7263974, DOI: 10.1016/j.jgo.2019.12.010.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerRisk calculatorLocal recurrenceBreast cancerOlder womenTumor characteristicsBreast cancer-specific outcomesReceipt of radiotherapyCancer-specific outcomesEarly breast cancerIndividual patient's riskBenefits of radiotherapyAdvisory CommitteeLife expectancyOnline risk calculatorLong-term survivalShared decision makingBenefit of RTOlder adult womenRadiotherapy statusCause mortalityOverall survivalRecurrence reductionFunctional statusPatient risk
2017
Duration of neoadjuvant endocrine therapy and breast cancer outcomes.
Mougalian S, Soulos P, Lannin D, Pusztai L, Gross C, Killelea B. Duration of neoadjuvant endocrine therapy and breast cancer outcomes. Journal Of Clinical Oncology 2017, 35: e12129-e12129. DOI: 10.1200/jco.2017.35.15_suppl.e12129.Peer-Reviewed Original ResearchNeoadjuvant endocrine therapyEndocrine therapyClinical stagePathologic stageNational Cancer Data BasePR-positive breast cancerHigher nodal stageNetwork cancer programsAdjuvant endocrine therapyMultiple comorbid conditionsBreast cancer outcomesPopulation of patientsType of surgeryPositive breast cancerSimilar response ratesNeoadjuvant chemotherapyUnderwent surgeryNodal stageComorbid conditionsCancer outcomesLarge tumorsCancer programsBreast cancerOlder womenPatients
2014
Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic Implications
Killelea BK, Long JB, Chagpar AB, Ma X, Wang R, Ross JS, Gross CP. Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic Implications. Journal Of The National Cancer Institute 2014, 106: dju159. PMID: 25031307, PMCID: PMC4155428, DOI: 10.1093/jnci/dju159.Peer-Reviewed Original ResearchConceptsEnd Results-MedicareBreast cancer stageCohort of womenEarly-stage tumorsBreast cancer screeningAdjunct imagingSignificant changesCancer screeningCancer stageIncidence rateBreast cancerAdjunct procedureOlder womenMedicare populationMedicare beneficiariesClinical practiceComputer-aided detectionPoisson regressionNational feeCohortBreast ultrasoundWomenEarlier cohortsLater cohortsMedicare spending
2013
The Cost of Breast Cancer Screening in the Medicare Population
Gross CP, Long JB, Ross JS, Abu-Khalaf MM, Wang R, Killelea BK, Gold HT, Chagpar AB, Ma X. The Cost of Breast Cancer Screening in the Medicare Population. JAMA Internal Medicine 2013, 173: 220-226. PMID: 23303200, PMCID: PMC3638736, DOI: 10.1001/jamainternmed.2013.1397.Peer-Reviewed Original ResearchConceptsBreast cancer screeningCancer screeningTreatment costsBetter breast cancer outcomesEnd Results-Medicare databaseService MedicareHigh screening costsWomen ages 66Breast cancer outcomesInitial cancer treatmentHospital referral region levelWomen 75 yearsInitial treatment costsEarly-stage cancerDigital screening mammographyCancer outcomesCancer incidenceCancer stageLowest quartileAge 66Breast cancerOlder womenMedicare populationComputer-aided detectionTreatment expenditures
2012
Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population
Soulos PR, Yu JB, Roberts KB, Raldow AC, Herrin J, Long JB, Gross CP. Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population. Journal Of Clinical Oncology 2012, 30: 1601-1607. PMID: 22393088, PMCID: PMC3383112, DOI: 10.1200/jco.2011.39.4890.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBreast NeoplasmsCombined Modality TherapyDisease-Free SurvivalFemaleHumansLife ExpectancyMastectomy, SegmentalMedicareNeoplasm InvasivenessNeoplasm StagingPrognosisRadiotherapy, AdjuvantRisk AssessmentSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsUse of RTAdjuvant radiation therapyRadiation therapyOlder womenRT useLife expectancyBreast cancerMedicare populationEnd Results-Medicare dataStage I breast cancerStrata of ageCooperative group trialsI breast cancerBreast cancer careStrata of patientsHealth system characteristicsLog-binomial regressionShort life expectancySample of womenTreatment guidelinesCancer careInclusion criteriaGroup trialsMedicare beneficiariesClinical practice